Bipolar II Disorder clinical trials
11 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
- Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
- Healthy Lifestyles for Bipolar Disorder
- A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
- Closed-Loop Deep Brain Stimulation for Treatment-Resistant Bipolar Depression
- Amplitude Titration to Improve ECT Clinical Outcomes
- Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
- Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
- FOCUS Bipolar: Families Opening Conversations for Understanding Signs
- Psychiatric Genotype/Phenotype Project Repository
- Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disorder
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Bipolar II Disorder” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.